Correlation between multiparametric magnetic resonance imaging with PI-RADS V2 score and anatomopathological analysis of patients undergoing prostatic biopsy




Prostate câncer; Magnetic resonance imaging; Biopsy.


Prostate cancer screening is based on clinical suspicion and the PSA antigen, which, when altered, directs the patient to perform a prostate biopsy. The use of multiparametric magnetic resonance imaging (mpNMR) with the PI-RADS v2 method helps to increase the accuracy of the biopsy. The aim of this study is to compare results of multiparametric magnetic resonance analysis based on the PIRADS v2 system with anatomopathological analysis of patients undergoing prostatic biopsy. This is a quantitative, observational, analytical, retrospective study. The analysis of the anatomopathological results of prostate biopsies of 60 patients previously submitted to mpNMR, from January 2017 to January 2019. The mean age of the 60 patients was 62.9 ± 10.0 (41-86), 45 of them (75%) had PSA levels greater than or equal to 4 ng/ml and in 15 patients (25%) the antigen was less than 4 ng/ml. The sensitivity of PSA in this study was 100% and its specificity was 28.8%. Sixty reports of prostatic biopsies were analyzed, in which their distribution showed 34 (56.6%) without alterations corresponding to a clinically significant tumor, the other 26 patients (43.3%) presented alterations. The sensitivity and specificity of mpMRI with the PI-RADS v2 system in detecting tumors was 75% and 80.7% respectively. It was demonstrated in this study that using mpMRI with the PI-RADS v2 system was efficient in estimating clinically significant tumors and helping in medical management.


Ahmed, H. U., Bosaily, A. E. S., Brown, L. C., Gabe, R., Kaplan, R., Parmar, M. K., Moraes, Y. C., Ward, K., Hindley, R. G., Freeman, A., Kirkham, A. P., Oldroyd, R., Parker, C., & Emberton, M. (2017). Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. The Lancet, 389(10071), 815-822.

Barentsz, J. O., Weinreb, J. C., Verma, S., Thoeny, H. C., Tempany, C. M., Shtern, F., Padhani, A. R., Margolis, D., Macura, K. J., Haider, M. A., Cornud, F., & Choyke, P. L. (2016). Synopsis of the PI-RADS v2 guidelines for multiparametric prostate magnetic resonance imaging and recommendations for use. European urology, 69(1), 41.

Barrett, T., Turkbey, B., & Choyke, P. L. (2015). PI-RADS version 2: what you need to know. Clinical radiology, 70(11), 1165-1176.

Borkowetz, A., Platzek, I., Toma, M., Renner, T., Herout, R., Baunacke, M., Laniado, M., Baretton, G., Froehner, M., Zastrow, S., & Wirth, M. (2016). Direct comparison of multiparametric magnetic resonance imaging (MRI) results with final histopathology in patients with proven prostate cancer in MRI/ultrasonography‐fusion biopsy. BJU international, 118(2), 213-220.

Descotes, J. L. (2019). Diagnosis of prostate cancer. Asian journal of urology, 6(2), 129-136.

Estimativa, I. N. C. A. (2019). Incidência de câncer no Brasil. Rio de Janeiro.

Estrela, C. (2018). Metodologia científica: ciência, ensino, pesquisa. Artes Médicas.

Gupta, R. T., Spilseth, B., & Froemming, A. T. (2016). How and why a generation of radiologists must be trained to accurately interpret prostate mpMRI. Abdominal Radiology, 41, 803-804.

Kasivisvanathan, V., Rannikko, A. S., Borghi, M., Panebianco, V., Mynderse, L. A., Vaarala, M. H., Briganti, A., Budaus, L., Hellawell, G., Hindley, R. G., Roobol, M. J., Eggener, S., Ghei, M., Villers, A., Bladou, F., Villeirs, G. M., Virdi, J., Boxler, S., Robert, G., Singh, P. B., Venderink, W., Hadaschik, B. A., Ruffion, A., Hu, J. C., Margolis, D., Crouzet, S., Klotz, L., Taneja, S. S., Pinto, P., Gill, I., Allen, C., Giganti, F., Freeman, A., Morris, S., Punwani, S., Williams, N. R., Graves-Brew, C., Deeks, J., Takwoingi, Y., Emberton, M., & Moore, C. M. (2018). MRI-targeted or standard biopsy for prostate-cancer diagnosis. New England Journal of Medicine, 378(19), 1767-1777.

Loeb, S. (2017). Biomarkers for prostate biopsy and risk stratification of patients with newly diagnosed prostate cancer. Urology practice, 4(4), 315-321.

Moldovan, P. C., Van den Broeck, T., Sylvester, R., Marconi, L., Bellmunt, J., Van den Bergh, R. C. N., Bolla, M., Briers, E., Cumberbatch, M. G., Fossati, N., Gross, T., Henry, A. M., Joniau, S., Van der Kwast, T. H., Matveev, V. B., Van der Poel, H. G., De Santis, M., Schoots, I. G., Wiegel, T., Yuan, C. Y., Conford, P., Mottet, N., Lam, T. B., & Rouvière, O. (2017). What is the negative predictive value of multiparametric magnetic resonance imaging in excluding prostate cancer at biopsy? A systematic review and meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel. European urology, 72(2), 250-266.

Mottet, N., Bellmunt, J., Bolla, M., Briers, E., Cumberbatch, M. G., De Santis, M., Fossati, N., Gross, T., Henry, A. M., Joniau, S., Lam, T. B., Mason, M. D., Maltveev, V. B., Moldovan, P. C., Van den Bergh, R. C. N., Van den Broeck, T., Van der Poel, H. G., Van der Kwast, T. H., Rouvière, O., Schoots, I. G., Wiegel, T., & Cornford, P. (2017). EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. European urology, 71(4), 618-629.

Nadler, R. B., Humphrey, P. A., Smith, D. S., Catalona, W. J., & Ratliff, T. L. (1995). Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. The Journal of urology, 154(2), 407-413.

Nardi, A. C., Nardozza Jr, A., Fonseca, C. E. C., Bretas, F. F. H., Truzzi, J. C. C. I., & Bernardo, W. M. (2014). Diretrizes Urologia AMB. Rio de Janeiro: Sociedade Brasileira de Urologia, 1.

Padhani, A. R., Weinreb, J., Rosenkrantz, A. B., Villeirs, G., Turkbey, B., & Barentsz, J. (2019). Prostate imaging-reporting and data system steering committee: PI-RADS v2 status update and future directions. European urology, 75(3), 385-396.

Pessoa, R., Werahera, P. N., & Kim, F. J. (2017). MD, MBA, FACS. Abernathy's Surgical Secrets: First South Asia Edition-E-Book, 450.

Rosenkrantz, A. B., Babb, J. S., Taneja, S. S., & Ream, J. M. (2016). Proposed adjustments to PI-RADS version 2 decision rules: impact on prostate cancer detection. Radiology, 283(1), 119-129.

Santiago, L. M., Luz, L. L., Silva, J. F. S. D., & Mattos, I. E. (2013). Prevalência e fatores associados à realização de exames de rastreamento para câncer de próstata em idosos de Juiz de Fora, MG, Brasil. Ciência & Saúde Coletiva, 18, 3535-3542.

Siddiqui, M. M., Rais-Bahrami, S., Turkbey, B., George, A. K., Rothwax, J., Shakir, N., Okoro, C., Raskolnikov, D., Parnes, H. L., Linehan, W. M., Mireno, M. J., Simon, R. M., Choyke, P. L., Wood, B. J., & Pinto, P. A. (2015). Comparison of MR/ultrasound fusion–guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. Jama, 313(4), 390-397.

Syed, J., Javier-desloges, J., Nguyen, K., Sheridan, A., Levi, A., Weinreb, J., & Sprenkle, P. (2017). The positive predictive value of PI-RADS 4 lesions stratified by lesion number in biopsy naïve men. Journal of Clinical Oncoloy.

Townsend, C. M., Beauchamp, R. D., Evers, B. M., & Mattox, K. L. (2010). Sabiston, Tratado de Cirurgia: A base biológica da prática cirúrgica moderna. In Sabiston, tratado de cirurgia: a base biológica da prática cirúrgica moderna (pp. 1083-1083).

Turkbey, B., Rosenkrantz, A. B., Haider, M. A., Padhani, A. R., Villeirs, G., Macura, K. J., Tempany, C. M., Choyke, P. L., Cornud, F., Margolis, D. J., Thoeny, H. C., Verma, S., Barentsz, J., & Weinreb, J. C. (2019). Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2. European urology, 76(3), 340-351.

Washino, S., Kobayashi, S., Okochi, T., Kameda, T., Konoshi, T., Miyagawa, T., Takayama, T., & Morita, T. (2018). Cancer detection rate of prebiopsy MRI with subsequent systematic and targeted biopsy are superior to non-targeting systematic biopsy without MRI in biopsy naive patients: a retrospective cohort study. BMC urology, 18(1), 1-8.

Weinreb, J. C., Barentsz, J. O., Choyke, P. L., Cornud, F., Haider, M. A., Macura, K. J., Margolis, D., Schnall, M. D., Shtern, F., Tempany, C. M., Thoeny, H. C., & Verma, S. (2016). PI-RADS prostate imaging–reporting and data system: 2015, version 2. European urology, 69(1), 16-40.

Zhang, L., Tang, M., Chen, S., Lei, X., Zhang, X., & Huan, Y. (2017). A meta-analysis of use of Prostate Imaging Reporting and Data System Version 2 (PI-RADS V2) with multiparametric MR imaging for the detection of prostate cancer. European radiology, 27, 5204-5214.



How to Cite

LEOCOVICK, L.; TREVISOL, J. V. B. .; FANTIN, G. A.; DALL AGNOL, M. A.; CALDAS, P. F. Correlation between multiparametric magnetic resonance imaging with PI-RADS V2 score and anatomopathological analysis of patients undergoing prostatic biopsy. Research, Society and Development, [S. l.], v. 12, n. 4, p. e29712441329, 2023. DOI: 10.33448/rsd-v12i4.41329. Disponível em: Acesso em: 9 jun. 2023.



Health Sciences